Pawel Fludzinski
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2019First federal award
$7.9MFederal grants as PI8 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
8 awards · $7.9M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Jul 24, 2025 | NIH | SBIR Phase II Dual Agonist Insulins for Treating Diabetics with Impaired Awareness ofHypoglycemia (IAH) | $999K | AMIDEBIO, LLC |
| Aug 26, 2024 | NIH | SBIR Phase II Dual Agonist Insulins for Treating Diabetics with Impaired Awareness ofHypoglycemia (IAH) | $930K | AMIDEBIO, LLC |
| Aug 17, 2023 | NIH | SBIR Phase II Long-acting Stable Glucagons for Treatment of Hyperinsulinism | $1.4M | AMIDEBIO, LLC |
| Sep 15, 2022 | NIH | SBIR Phase II Long-acting Stable Glucagons for Treatment of Hyperinsulinism | $2.7M | AMIDEBIO, LLC |
| Feb 17, 2022 | NIH | SBIR Phase I Novel Glucose Responsive Insulin for Improved Treatment of Diabetes | $116K | AMIDEBIO, LLC |
| Feb 26, 2021 | NIH | SBIR Phase I Novel Glucose Responsive Insulin for Improved Treatment of Diabetes | $184K | AMIDEBIO, LLC |
| Aug 12, 2020 | NIH | SBIR Phase II Stable Glucagon for Treatment of Hyperinsulinism | $817K | AMIDEBIO, LLC |
| Sep 13, 2019 | NIH | SBIR Phase II Stable Glucagon for Treatment of Hyperinsulinism | $740K | AMIDEBIO, LLC |
Peer ranks
Federal funding#113
Awards as PI#190
Patents#273
Companies
- AMIDEBIO, LLCLinked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.